Page last updated: 2024-08-21

pyrazines and Disease Exacerbation

pyrazines has been researched along with Disease Exacerbation in 183 studies

Research

Studies (183)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (1.09)18.2507
2000's65 (35.52)29.6817
2010's100 (54.64)24.3611
2020's16 (8.74)2.80

Authors

AuthorsStudies
Gaspar, Z; Kiss-Dala, N; Lakatos, B; Lenart, KS; Petrik, B; Szabo, BG; Szlavik, J; Valyi-Nagy, I1
Abdul Wahab, S; Adnan, NA; Cheng, JT; Chidambaram, SK; Chow, TS; Chuah, CH; Hor, CP; Ker, HB; Lee, HG; Lee, KS; Mustafa, M; Ng, TK; Nordin, N; Ong, SM; Tee, TY; Zaid, M; Zaidan, NZ1
Budde, LE; Calvo, R; Champion, R; Coleman, M; Geethakumari, PR; Higgins, K; Lam, S; Levy, MY; Lossos, IS; Ma, S; Patti, C; Strati, P1
Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B1
Casasnovas, O; Damaj, G; Davies, A; Doorduijn, JK; Dupuis, J; Długosz-Danecka, M; Eek, R; Frigault, MM; Goy, A; Izumi, R; Jacobsen, E; Jain, P; Kater, AP; Lamy, T; Le Gouill, S; Morschhauser, F; Nguyen, D; Oberic, L; Panizo, C; Patel, P; Robak, T; Rule, S; Shah, B; Smith, SD; Wang, M; Yin, M; Zinzani, PL1
Cai, S; Chew, LA; Jiang, Y; Jin, Y; Khanna, R; Ruan, Y; Wen, C; Xu, Z; Yu, J; Zhong, K1
Jin, Q; Liu, Z; Luo, Q; Xiong, C; Yan, L; Yu, X; Zhang, Y; Zhao, Q; Zhao, Z1
Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R1
Ge, J; Li, H; Liu, Z1
Amin, EK; Austin, ED; Colglazier, E; Fineman, JR; Hemnes, AR; Leary, PJ; Nawaytou, H; Parker, C; Teitel, D1
Inoue, KI; Sagawa, T; Takano, H1
Danilov, AV; Persky, DO1
Chen, J; Fan, J; Wang, Y; Zhan, Q; Zhang, J; Zhang, L; Zhang, W; Zhao, D1
Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A1
Badillo, M; Flowers, C; Jain, P; Kanagal-Shamanna, R; Lee, HJ; Li, S; Nair, R; Nastoupil, L; Navsaria, L; Ok, CY; Patel, KM; Tang, G; Vega, F; Wang, L; Wang, ML; Yin, CC; Zhang, S1
Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V1
Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T1
Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W1
Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R1
Fayad, L; Fowler, N; Jain, P; Kanagal-Shamanna, R; Medeiros, LJ; Nastoupil, L; Oki, Y; Romaguera, J; San Lucas, FA; Wang, M; Westin, JR1
Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Scott, A1
Asimus, S; Brown, MN; Clarke, GW; Cunoosamy, DM; Ersdal, E; Fagerås, M; Greenaway, S; Hegelund-Myrbäck, T; Jansson, P; Korsback, K; Kristensson, C; Kurian, N; Lundin, S; Make, BJ; Palmér, R; Pardali, K; Patel, NR; Rennard, SI; Siew, L; Taib, Z; Wise, RA1
Assouline, S; Burke, JM; Chen, R; Essell, J; Patel-Donnelly, D; Sharman, J; Shi, W; Shustov, A; Yang, J; Ye, W1
Alhalouli, T; Bueso-Ramos, C; Burger, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, HM; Keating, M; Khoury, JD; Luthra, R; Medeiros, LJ; Patel, KP; Routbort, M; Wierda, W1
Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF1
Andrews, JA; Cockcroft, BM; Cudkowicz, ME; Hardiman, O; Lee, JH; Malik, FI; Meng, L; Rudnicki, SA; Shefner, JM; Wolff, AA1
Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S1
Chen, J; Lin, J; Zeng, Z1
Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F1
Cusick, T; Fisher, JE; Glantschnig, H; Kimmel, DB; Langdon, RB; Li, Z; Mu, J; Pennypacker, BL; Scott, KR; Shen, X; Zhang, BB1
Camidge, DR; Ching, KA; Christensen, JG; Clark, JW; Diamond, JR; Eckhardt, SG; Kanteti, R; Lira, ME; LoRusso, PM; Salgia, R; Schoenmakers, EF; Varella-Garcia, M; Wilner, K; Xu, LG1
Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S1
Charbonnel, B; Dejager, S; Schweizer, A1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A1
Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G1
Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L1
Chen, SJ; Guo, Y; Janin, A; Leboeuf, C; Romero, M; Wang, L; Wu, LL; Xue, K; Yan, ZX; Zhang, QL; Zhao, WL1
An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D1
Iyengar, R; Luker, GD; Luker, KE; Moudgil, P; Nyati, S; Rehemtulla, A; Stacer, AC1
Arai, S; Iwakura, Y; Kagoya, Y; Kataoka, K; Kobayashi, H; Kumano, K; Kurokawa, M; Nakagawa, M; Saito, T; Yoshimi, A1
Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S1
Bryant, J; Clegg, A; Cooper, K; Picot, J1
Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z1
Alpaugh, RK; Cheng, JD; Cohen, SJ; Cooper, H; Denlinger, CS; Engstrom, PF; Lewis, NL; Li, T; Meropol, NJ; Weiner, LM; Wright, JJ1
Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH1
Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M1
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E1
Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST1
Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K1
Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L1
Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H1
Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K1
Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W1
Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I1
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ1
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G1
Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M1
Chinen, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M; Tatekawa, S; Tsukamoto, T; Yamamoto-Sugitani, M1
Hobeika, L; Self, SE; Velez, JC1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ1
Li, Y; Qin, H; Tao, Q; Wang, H; Wang, Y; Wang, Z; Xiao, W; Xiong, S; Zhai, Z; Zhang, L1
Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S1
Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A1
Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC1
Anderson, KC; Bianchini, G; Cottini, F; Hideshima, T; Richardson, PG; Suzuki, R; Tai, YT; Tonon, G1
Arezzo, J; Bradshaw, KL; Bril, V; Gordon, RJ; Junor, RW; Nash, M; Polydefkis, M; Shaibani, A1
Adzerikho, I; Channick, R; Chin, KM; Di Scala, L; Frey, A; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Liu, J; McLaughlin, VV; Moiseeva, O; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, V; Zeng, X1
Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y1
Bertoglio, J; Bréard, J; Mérino, D; Micheau, O; Ndozangue-Touriguine, O; Sebbagh, M1
Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H1
Durie, BG1
Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P1
Golenkov, AK; Mitina, TA1
Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS1
Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH1
Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK1
Abdalla, S; Hu, M; Karadimitris, A; Kotsianidis, I; Melo, V; Naresh, K; Rahemtulla, A; Reid, A; Spanoudakis, E; Terpos, E1
Guerciolini, R; Hsieh, FY; Miwa, G; Pekol, TM; Tengstrand, E1
Avvisati, G1
Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J1
Berenson, JR1
Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR1
Lattin, G; Sanders, O; Timpone, V1
Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y1
Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT1
Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB1
Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM1
Bode, BW1
Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H1
Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM1
Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P1
Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L1
Asmar, L; Barrera, D; Boehm, KA; Boston, J; Boyd, T; Cochran, EW; Di Bella, N; Dien, PY; Kolibaba, K; Lyons, R; Raju, R; Schlegel, PJ; Taetle, R; Vukelja, SJ; Wang, Y1
Blumel, S; Butos, J; Cooper, B; Dumitrescu, O; Evens, AM; Gerecitano, J; Gonen, M; Hamlin, P; Mac-Gregor Cortelli, B; Moskowitz, C; Neylon, E; O'Connor, OA; Portlock, C; Sarasohn, D; Straus, D; Vose, J; Winter, J; Wright, J; Zelenetz, AD1
Duong, TQ; Jung, I; Keller, C; Kilcoyne, A; Lin, AL; Morgan, WW; Nelon, LD; Nowak, BM; Ohshima-Hosoyama, S; Prajapati, SI; Rubin, BP; Samano, AK; Taniguchi, E; Togao, O; Whitney, TG1
Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S1
Jagannath, S; Mazumder, A; Vesole, DH1
Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE1
Cefalu, WT1
Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK1
Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH1
Kurzrock, R; Subbiah, V; Trent, JC1
Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F1
Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M1
Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P1
Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A1
Bagshaw, M; Banwait, R; Ghobrial, IM; Leduc, R; Leleu, X; Roper, N; Weller, E; Xie, W1
Bladé, J; Hajek, R; Harousseau, JL; Lantz, KC; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH1
Hayashi, T; Ikeda, H; Imai, K; Ishida, T; Kawakami, K; Kobayashi, T; Nishimura, S; Shinomura, Y; Takahashi, F; Yasui, H1
Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M1
Ahsan, A; Arai, Y; Argiris, A; Chen, Z; Cooley-Zgela, T; Duffy, AG; Jang, M; Kannabiran, VR; Kim, SW; Kummar, S; Nyati, MK; Ramanand, SG; Rudy, SF; Simone, NL; Suksta, N; Van Waes, C; Wright, JJ; Yang, X1
Bladé, J; Cakana, A; Comenzo, RL; Dubrey, SW; Elsayed, Y; Enny, C; Fermand, JP; Hassoun, H; Heffner, LT; Hegenbart, U; Liu, X; Merlini, G; Mortimer, S; Palladini, G; Ramaswami, P; Reece, DE; Sanchorawala, V; Van De Velde, H; Vescio, RA1
Anolik, JH; Barnard, J; Conley, T; Goldman, BI; Ichikawa, HT; Jiang, J; Kirk, CJ; Lee, S; Looney, RJ; Muchamuel, T; Nevarez, S; Owen, T1
Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T1
Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C1
Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH1
Ge, WP; Liu, N; Lu, D; Ma, CM; Qin, C; Shao, HT; Zhang, LF; Zhang, X1
Cao, Q; Dudek, AZ; Wang, H1
Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN1
Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ1
Argiris, A; Arun, P; Feldman, LE; Forastiere, AA; Gilbert, J; Haigentz, M; Jang, M; Lee, JW; Van Waes, C1
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF1
Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S1
Baas, P; Busacca, S; Cakana, A; Donnellan, P; Fennell, DA; McCaffrey, J; McDowell, C; Meerbeeck, JV; Moulton, B; O'Byrne, KJ; Webb, G1
Botton, Sd; Boué, F; Bourhis, JH; Crickx, E; Danu, A; Ghez, D; Mariette, X; Miceli, C; Moreau, P; Pasquier, F; Ribrag, V; Wittnebel, S1
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B1
Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P1
Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP1
Ludwig, H; Sonneveld, P1
Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F1
Bakris, GL; Flynn, C1
Faix, JD1
Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE1
Kyle, RA; Rajkumar, SV1
Cardinale, G; Gervasi, F; Pagnucco, G1
Anderson, KC; Hideshima, T; Rajkumar, SV; Richardson, PG1
Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W1
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Adachi, M; Imai, K; Kawamura, R; Minami, T; Shinomura, Y; Zhang, Y1
Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J1
Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M1
Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T1
Gamradt, SC; Gates, JJ; Lieberman, JR; Whang, PG1
Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA1
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH1
Fayad, L; Pro, B; Younes, A1
Chim, CS; Ooi, GC1
Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S1
Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R1
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ1
Degendorfer, P; Gomez-Abuin, G; Moore, MJ; Pond, G; Stadler, WM; Winquist, E; Wright, J1
Anderson, KC1
Engel, J; Fagbemi, S; Olatosi, B; Onitilo, AA1
Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D1
Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Burns, MJ; Cavallo, F; Elice, F; Esseltine, D; Neuwirth, R; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M1
Bhandari, M; Jagannath, S1
Orlowski, RZ; Voorhees, PM1
Bartlett, NL; Blum, KA; Canellos, GP; Cheson, BD; Johnson, JL; Niedzwiecki, D1
Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH1
Faiman, B1
Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F1
Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R1
Anderson, KC; Carrasco, DR; Dranoff, G; Jinushi, M; Munshi, NC; Neuberg, D; Prabhala, RH; Ritz, J; Tai, YT; Vanneman, M1
Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H1
Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT1
Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ1
Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
Chim, CS; Hwang, YY; Shek, TW1
Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP1
Stevenson, LW1
Bourge, R; Carson, P; Feldman, AM; Holubkov, R; Jaski, B; Loftus, S; Soran, O; White, BG; Young, JD1
Ali, IU; Herbert, BS; Kopelovich, L; Passons, CM; Shay, JW; Wright, AC; Wright, WE1
Alavijeh, M; Böhme, GA; Boireau, A; Bordier, F; Brealey, C; Briet, D; Canton, T; Debono, MW; Jahn, G; Jimonet, P; Laville, M; Le Guern, S; Mignani, S; Pratt, J; Roberts, S; Roux, M; Stutzmann, JM; Stygall, J; Vuilhorgne, M1

Reviews

18 review(s) available for pyrazines and Disease Exacerbation

ArticleYear
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
    BMC pulmonary medicine, 2019, Dec-19, Volume: 19, Issue:1

    Topics: Acetamides; Adult; Anticoagulants; Antihypertensive Agents; Cardiac Catheterization; Disease Progression; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Tolerance; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pulmonary Edema; Pulmonary Veno-Occlusive Disease; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Walk Test

2019
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:12

    Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines

2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    British journal of haematology, 2021, Volume: 193, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Disease Progression; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrazines; Safety; Treatment Outcome; United States; United States Food and Drug Administration

2021
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
    Scientific reports, 2021, 05-26, Volume: 11, Issue:1

    Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Intensive Care Units; Pyrazines; SARS-CoV-2; Survival Analysis; Treatment Outcome; Viral Load

2021
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
    Annals of hematology, 2013, Volume: 92, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine

2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Hospital practice (1995), 2013, Volume: 41, Issue:2

    Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin

2013
Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Immunotherapy, 2014, Volume: 6, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting

2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
    Blood, 2014, Aug-28, Volume: 124, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2014
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    The oncologist, 2015, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide

2015
Defining the importance of daily glycemic control and implications for type 2 diabetes management.
    Postgraduate medicine, 2009, Volume: 121, Issue:5

    Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles

2009
The physiologic role of incretin hormones: clinical applications.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil

2010
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
    Leukemia research, 2012, Volume: 36 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors

2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
    Nature reviews. Nephrology, 2013, Volume: 9, Issue:3

    Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin

2013
Multiple myeloma.
    The New England journal of medicine, 2004, Oct-28, Volume: 351, Issue:18

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide

2004
Targeting multiple myeloma cells and their bone marrow microenvironment.
    Annals of the New York Academy of Sciences, 2004, Volume: 1028

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide

2004
Proteasome inhibition as a novel therapeutic target in human cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin

2005
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7 Suppl 4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2007
Clinical updates and nursing considerations for patients with multiple myeloma.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome

2007

Trials

72 trial(s) available for pyrazines and Disease Exacerbation

ArticleYear
Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-24, Volume: 75, Issue:1

    Topics: Amides; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hypoxia; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome

2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    British journal of haematology, 2022, Volume: 199, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Benzamides; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome

2022
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
    Leukemia, 2019, Volume: 33, Issue:11

    Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pyrazines; Time Factors; Treatment Outcome

2019
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Chest, 2021, Volume: 160, Issue:1

    Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Morbidity; Prognosis; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Survival Rate

2021
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
    The European respiratory journal, 2017, Volume: 50, Issue:2

    Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis

2017
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
    International journal of chronic obstructive pulmonary disease, 2018, Volume: 13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Benzamides; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Humans; Lung; Macrophages, Alveolar; Male; Middle Aged; Mitogen-Activated Protein Kinase 14; Proof of Concept Study; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazines; Time Factors; Treatment Outcome; Young Adult

2018
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Syk Kinase; Time Factors

2018
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
    European journal of heart failure, 2019, Volume: 21, Issue:3

    Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome

2019
A phase III trial of
    Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019, Volume: 0, Issue:0

    Topics: Adult; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Muscle Strength; Muscle, Skeletal; Pyrazines; Treatment Outcome

2019
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy

2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Blood, 2013, Aug-22, Volume: 122, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome

2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-10, Volume: 31, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Recurrence; Thalidomide

2013
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Boronic Acids; Bortezomib; Cholangiocarcinoma; Disease Progression; Female; Follow-Up Studies; Gallbladder Neoplasms; Humans; Male; Middle Aged; Proteasome Inhibitors; Pyrazines; Survival Rate; Time Factors; Treatment Outcome

2014
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome

2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous

2014
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
    Blood, 2014, Aug-07, Volume: 124, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome

2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015
Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
    Journal of the peripheral nervous system : JPNS, 2015, Volume: 20, Issue:4

    Topics: Aged; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Pyrazines; Quality of Life; Spiro Compounds; Treatment Outcome

2015
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    The New England journal of medicine, 2015, Dec-24, Volume: 373, Issue:26

    Topics: Acetamides; Aged; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Prodrugs; Pyrazines

2015
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature

2016
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome

2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome

2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    British journal of haematology, 2009, Volume: 144, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome

2009
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis

2010
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia

2010
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    British journal of haematology, 2009, Volume: 147, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome

2009
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence

2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome

2010
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome

2009
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Blood, 2010, Jan-07, Volume: 115, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2010
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
    Blood, 2010, Jan-21, Volume: 115, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome

2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jan-15, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome

2010
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms

2010
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
    Annals of hematology, 2010, Volume: 89, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine

2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States

2012
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
    Cancer, 2011, Aug-01, Volume: 117, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis

2011
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
    Cancer, 2011, Aug-15, Volume: 117, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence

2011
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Male; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia

2011
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
    British journal of haematology, 2011, Volume: 154, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome

2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Cytokines; Disease Progression; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Radiotherapy, Intensity-Modulated; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Treatment Outcome

2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:11

    Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Diseases; Humans; Kidney Diseases; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Treatment Outcome

2011
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Neuro-oncology, 2012, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat

2012
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2012
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines

2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2012
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
    Clinical nuclear medicine, 2012, Volume: 37, Issue:6

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure

2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Head & neck, 2013, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Squamous Cell; Cytokines; Disease Progression; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; NF-kappa B; Pyrazines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome

2013
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2012
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9

    Topics: Aged; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survival Rate

2012
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors

2013
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome

2004
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Cancer, 2005, Jun-15, Volume: 103, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure

2005
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    The New England journal of medicine, 2005, Jun-16, Volume: 352, Issue:24

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate

2005
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53

2005
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome

2005
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Journal of Korean medical science, 2005, Volume: 20, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors

2005
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5

    Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome

2006
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
    Blood, 2006, Feb-15, Volume: 107, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Recurrence; Stem Cell Transplantation; Treatment Outcome

2006
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2007
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
    Investigational new drugs, 2007, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Survival Analysis; Urologic Neoplasms; Urothelium

2007
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome

2006
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    British journal of haematology, 2007, Volume: 137, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia

2007
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:7

    Topics: Adult; Boronic Acids; Bortezomib; Disease Progression; Female; Hodgkin Disease; Humans; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis; Treatment Failure

2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines

2007
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States

2007
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome

2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms

2008
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Cancer, 2008, Apr-01, Volume: 112, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide

2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Haematologica, 2008, Volume: 93, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis

2008
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    British journal of haematology, 2008, Volume: 141, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome

2008
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome

2008
Effect of inotrope withdrawal on morbidity and mortality in patients with chronic heart failure: results of the vesnarinone trial withdrawal substudy. Vest Withdrawal Substudy Group.
    Journal of cardiac failure, 1999, Volume: 5, Issue:3

    Topics: Cardiotonic Agents; Cause of Death; Chronic Disease; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Middle Aged; Myocardial Contraction; Pyrazines; Quinolines; Retrospective Studies; Substance Withdrawal Syndrome; Survival Rate

1999

Other Studies

93 other study(ies) available for pyrazines and Disease Exacerbation

ArticleYear
Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary.
    GeroScience, 2021, Volume: 43, Issue:5

    Topics: Amides; Cohort Studies; COVID-19 Drug Treatment; Disease Progression; Humans; Hungary; Prospective Studies; Pyrazines; SARS-CoV-2; Treatment Outcome

2021
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
    Acta clinica Croatica, 2022, Volume: 61, Issue:3

    Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pneumonia; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome

2022
Tetramethylpyrazine Reduces Epileptogenesis Progression in Electrical Kindling Models by Modulating Hippocampal Excitatory Neurotransmission.
    ACS chemical neuroscience, 2019, 12-18, Volume: 10, Issue:12

    Topics: Animals; Anticonvulsants; Anxiety; CA1 Region, Hippocampal; Calcium Channel Blockers; Calcium Channels; Convulsants; Disease Progression; Electric Stimulation; Electroshock; Epilepsy, Complex Partial; Excitatory Postsynaptic Potentials; Exploratory Behavior; Ion Transport; Kindling, Neurologic; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Pentylenetetrazole; Pyrazines; Recognition, Psychology; Seizures; Sodium Channels

2019
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation.
    International journal of molecular sciences, 2020, Feb-05, Volume: 21, Issue:3

    Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic

2020
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
    American journal of respiratory and critical care medicine, 2020, 12-01, Volume: 202, Issue:11

    Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents

2020
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
    Critical care (London, England), 2020, 08-18, Volume: 24, Issue:1

    Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2

2020
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
    Molecular carcinogenesis, 2021, Volume: 60, Issue:2

    Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Progression; Esophageal Neoplasms; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2021
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
    Endocrine journal, 2021, Apr-28, Volume: 68, Issue:4

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

2021
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
    American journal of hematology, 2021, 05-01, Volume: 96, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Substitution; Exome Sequencing; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Mutation; Protein Kinase Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Sample Size; Treatment Outcome; Withholding Treatment

2021
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
    Current problems in cancer, 2021, Volume: 45, Issue:6

    Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine

2021
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult

2021
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    British journal of haematology, 2018, Volume: 182, Issue:5

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Benzamides; Disease Progression; Drug Resistance; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome

2018
Drug therapy: On the treatment trail for ALS.
    Nature, 2017, 10-18, Volume: 550, Issue:7676

    Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Edaravone; Genetic Therapy; Humans; Imidazoles; Mesenchymal Stem Cells; Motor Neurons; Neuroglia; Off-Label Use; Oligoribonucleotides, Antisense; Piperidines; Precision Medicine; Pyrazines; Pyridines; Riluzole; RNAi Therapeutics; Stem Cell Transplantation; Superoxide Dismutase; Thiazoles; United States; United States Food and Drug Administration

2017
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer, 2019, 02-15, Volume: 125, Issue:4

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Piperidines; Prognosis; Pyrazines; Pyrazoles; Pyrimidines

2019
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
    Leukemia research, 2013, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A

2013
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:10

    Topics: Absorptiometry, Photon; Animals; Bone Density; Disease Progression; Estrogens; Female; Femur; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Ovariectomy; Pyrazines; Rats; Sitagliptin Phosphate; Thiazolidinediones; Triazoles

2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Heterozygote; Humans; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Methionine; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazines; Receptor Protein-Tyrosine Kinases; Sequence Analysis, DNA; Threonine; Treatment Failure; Triazoles

2013
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine

2013
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy

2013
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
    Leukemia, 2014, Volume: 28, Issue:4

    Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, T-Cell, Peripheral; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazines

2014
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous

2014
NanoLuc reporter for dual luciferase imaging in living animals.
    Molecular imaging, 2013, Volume: 12, Issue:7

    Topics: Animals; Breast Neoplasms; Cell Line; Disease Progression; Female; Heterografts; Imidazoles; Luciferases; Luciferases, Firefly; Luminescent Measurements; Mice; Molecular Imaging; Neoplasm Transplantation; Pyrazines; Signal Transduction; Substrate Specificity; Transfection; Transforming Growth Factor beta

2013
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:2

    Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Disease Progression; Female; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Middle Aged; NF-kappa B; Phenotype; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha

2014
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
    The Journal of endocrinology, 2014, Volume: 220, Issue:3

    Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles

2014
Comparative cost-effectiveness models for the treatment of multiple myeloma.
    International journal of technology assessment in health care, 2014, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom

2014
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
    Cardiovascular diabetology, 2014, Feb-04, Volume: 13

    Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles

2014
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy

2014
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:5

    Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome

2014
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    American journal of hematology, 2014, Volume: 89, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
    Haematologica, 2014, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome

2014
CSNK1α1 mediates malignant plasma cell survival.
    Leukemia, 2015, Volume: 29, Issue:2

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction

2015
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous

2014
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib

2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide

2014
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Journal of medical case reports, 2014, Sep-08, Volume: 8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous

2014
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
    Annals of hematology, 2015, Volume: 94, Issue:4

    Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Pyrazines

2015
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    BMC nephrology, 2014, Sep-30, Volume: 15

    Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies

2014
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
    Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Communication; Cell Growth Processes; Cytokines; Disease Progression; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Pyrazines; T-Lymphocytes, Regulatory; Treatment Outcome

2015
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome

2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9

2015
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
    Cancer discovery, 2015, Volume: 5, Issue:9

    Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Chromosomal Instability; Cluster Analysis; Disease Progression; DNA Damage; DNA Replication; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxidative Stress; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazines; Reactive Oxygen Species; Sulfones

2015
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Oncogene, 2008, Oct-09, Volume: 27, Issue:46

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Carcinoma; Cell Membrane Permeability; Colonic Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mitochondria; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein

2008
Treatment of myeloma--are we making progress?
    The New England journal of medicine, 2008, Aug-28, Volume: 359, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines

2008
Infiltration of the spinal cord in a patient with multiple myeloma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-01, Volume: 26, Issue:25

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms

2008
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
    Terapevticheskii arkhiv, 2008, Volume: 80, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome

2008
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.
    PloS one, 2008, Volume: 3, Issue:11

    Topics: Absorption; Administration, Oral; Alanine Transaminase; Amides; Animals; Arenaviridae Infections; Aspartate Aminotransferases; Cricetinae; Disease Models, Animal; Disease Progression; Female; Hemorrhagic Fevers, Viral; Interferon Type I; Liver Diseases; Mesocricetus; Pichinde virus; Pyrazines; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load

2008
Regulation of multiple myeloma survival and progression by CD1d.
    Blood, 2009, Mar-12, Volume: 113, Issue:11

    Topics: Antibodies, Monoclonal; Antigens, CD1d; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Aggregation; Cell Survival; Dexamethasone; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Plasma Cells; Pyrazines; Tumor Cells, Cultured

2009
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
    Journal of pharmaceutical and biomedical analysis, 2009, Jan-15, Volume: 49, Issue:1

    Topics: Aged; Antineoplastic Agents; Apolipoprotein C-I; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Chromatography, Liquid; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Mass Spectrometry; Middle Aged; Molecular Weight; Multiple Myeloma; Protein Isoforms; Pyrazines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Time Factors

2009
Bortezomib plus melphalan and prednisone for multiple myeloma.
    The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide

2008
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
    International journal of hematology, 2009, Volume: 89, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome

2009
Hematology: Bortezomib in newly diagnosed multiple myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome

2009
Worsening low back pain.
    The Journal of family practice, 2009, Volume: 58, Issue:7

    Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Family Practice; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Function Tests; Low Back Pain; Male; Multiple Myeloma; Pain Measurement; Plasmapheresis; Pyrazines; Renal Dialysis; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed

2009
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence

2010
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:6

    Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome

2009
Treatment of multiple myeloma: 2009 update.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2009
Functional evaluation of therapeutic response for a mouse model of medulloblastoma.
    Transgenic research, 2010, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Ataxia; Boronic Acids; Bortezomib; Cerebellar Neoplasms; Disease Models, Animal; Disease Progression; Drug Screening Assays, Antitumor; Gait Disorders, Neurologic; Lameness, Animal; Magnetic Resonance Imaging; Medulloblastoma; Mice; Mice, Knockout; Patched Receptors; Patched-1 Receptor; Protease Inhibitors; Psychomotor Performance; Pyrazines; Receptors, Cell Surface

2010
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide

2010
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat

2010
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
    Annals of hematology, 2010, Volume: 89, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors

2010
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure

2010
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Oncology, 2010, Volume: 79, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome

2010
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies

2011
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease Progression; Drug Therapy, Combination; Graft vs Tumor Effect; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2011
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:2

    Topics: Animals; Antibody-Producing Cells; Autoantibodies; Boronic Acids; Bortezomib; Disease Progression; Humans; Interferon Type I; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Oligopeptides; Protease Inhibitors; Pyrazines

2012
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome

2012
Ginsenoside-Rb1 and tetramethylpyrazine phosphate act synergistically to prevent dilated cardiomyopathy in cTnTR141W transgenic mice.
    Journal of cardiovascular pharmacology, 2012, Volume: 59, Issue:5

    Topics: Animals; Blotting, Western; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; Cardiomyopathy, Dilated; Disease Models, Animal; Disease Progression; Drug Synergism; Drug Therapy, Combination; Echocardiography; Gene Expression Regulation; Ginsenosides; Heparin-binding EGF-like Growth Factor; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction

2012
Minor clone provides a reservoir for relapse in multiple myeloma.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53

2013
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome

2013
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Salvage Therapy; Stem Cell Transplantation

2013
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
    British journal of haematology, 2013, Volume: 160, Issue:2

    Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia

2013
Multiple myeloma, version 1.2013.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat

2013
Bortezomib in multiple myeloma.
    The New England journal of medicine, 2003, Sep-25, Volume: 349, Issue:13

    Topics: Boronic Acids; Bortezomib; Disease Progression; Humans; Multiple Myeloma; Paraproteins; Protease Inhibitors; Pyrazines

2003
Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
    Prescrire international, 2005, Volume: 14, Issue:77

    Topics: Antineoplastic Agents; Boronic Acids; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Humans; Multiple Myeloma; Pyrazines; Treatment Outcome

2005
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-15, Volume: 11, Issue:14

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; Disease Progression; DNA Damage; Drug Interactions; Humans; Mice; Mice, Nude; Oxidative Stress; Pyrazines; Reactive Oxygen Species; Sulindac; Transplantation, Heterologous

2005
Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
    Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:4

    Topics: Animals; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Disease Progression; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2005
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia

2005
Bulbar palsy in multiple myeloma.
    Haematologica, 2005, Volume: 90, Issue:12 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine

2005
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome

2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-15, Volume: 12, Issue:10

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Approval; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; United States; United States Food and Drug Administration

2006
New drugs for multiple myeloma.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome

2006
Community experience with bortezomib in patients with multiple myeloma.
    American journal of hematology, 2007, Volume: 82, Issue:7

    Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Community Medicine; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate

2007
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous

2007
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
    American journal of hematology, 2007, Volume: 82, Issue:9

    Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials as Topic; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Predictive Value of Tests; Pyrazines; Time Factors

2007
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:5

    Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome

2007
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy

2007
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Jan-29, Volume: 105, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cross-Priming; Dendritic Cells; Disease Progression; Histocompatibility Antigens Class I; Humans; Isoantibodies; Ligands; Multiple Myeloma; Prognosis; Pyrazines; Tumor Cells, Cultured

2008
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
    Onkologie, 2008, Volume: 31, Issue:1-2

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin

2008
Multiple myeloma with testicular involvement.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome

2008
Inotropic therapy for heart failure.
    The New England journal of medicine, 1998, Dec-17, Volume: 339, Issue:25

    Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Death, Sudden; Disease Progression; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Pyrazines; Quinolines

1998
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
    Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1

    Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Disease Progression; DNA, Complementary; Eflornithine; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Li-Fraumeni Syndrome; Oligodeoxyribonucleotides, Antisense; Point Mutation; Pyrazines; Reverse Transcriptase Inhibitors; Tamoxifen; Telomerase; Thiones; Thiophenes; Transformation, Genetic; Tretinoin

2001
RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:1

    Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Disease Progression; Electrophysiology; Electroshock; Excitatory Amino Acid Antagonists; Glutamic Acid; Imidazoles; In Vitro Techniques; Longevity; Mice; Mice, Transgenic; Muscle, Skeletal; Neurons; Patch-Clamp Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Superoxide Dismutase

2001